Study finds existing drugs that could treat COVID-19

Study finds existing drugs that could treat COVID-19

Posted by Valerie Walters on Jul 29, 2020 8:00 am

A Nature study authored by a global team of scientists at Sanford Burnham Prebys Medical Discovery Institute, has identified 21 existing drugs that stop the replication of SARS-CoV-2, the virus that causes COVID-19.

The study reported a high-throughput analysis of approximately 12,000 known drugs evaluated for activity against SARS-CoV-2 replication, revealing approximately 100 known drugs with antiviral activities. Of these, 21 drugs were determined to be effective at concentrations that could be safely achieved in patients. Several major target classes were found to be enriched for activity in this analysis, including ion channels, GPCRs, proteases, and kinases. Notably, four of these compounds were found to work synergistically with remdesivir, a current standard-of-care treatment for COVID-19. The pharmacokinetic properties of each individual compound, including factors such as serum protein binding and bioavailability in the lung, will impact potential in vivo antiviral efficacy.


Dose relationship antiviral


Of the 21 drugs that were effective at blocking viral replication, the scientists found:

● 13 have previously entered clinical trials for other indications and are effective at concentrations, or doses, that could potentially be safely achieved in COVID-19 patients.

● Two are already FDA approved: astemizole (allergies), clofazamine (leprosy), and remdesivir has received Emergency Use Authorization from the agency (COVID-19).

● Four worked synergistically with remdesivir, including the chloroquine derivative hanfangchin A (tetrandrine), an antimalarial drug that has reached Phase 3 clinical trials.

List of the 21 most potent compounds validated in dose response across multiple cell lines reported by the study:

Compound Name Known Targets Target Class More Information
Clofazimine mycobacterial DNA (ABCB1) Unspecified
Astemizole Histamine H1 receptor GPCR
Remdesivir viral RNA polymerase Antiviral
Hanfangchin A (Tetrandrine) calcium channels (non-selective) Ion channel
Apilimod PIKfyve Phosphoinositide kinase
MLN-3897 C-C Motif Chemokine Receptor 1 (CCR1) GPCR
ONO 5334 cathepsin K (CTSK) Cysteine protease
Elopiprazole D2 and D3 dopamine receptors (DRD2, DRD3), 5-HT1A serotonin receptor (HTR1A) GPCR
SDZ-62-434 PAF /PI3K/Akt/NF-kappaB pathway GPCR
YH-1238 H,K-ATPase (ATP4A, ATP4B) Proton Pump
DS-6930 PPARγ Nuclear receptor
N-tert-Butylisoquine (GSK369796) hERG potassium ion channel (KCNH2) Chloroquine derivative, Ion channel
R 82913 reverse transcriptase Antiviral
VBY-825 cathepsins B, L, S and V (CTSB, CTSL, CTSS, CTSV) Cysteine protease
8-(3-Chlorostyryl)caffeine A2A adenosine receptor (ADORA2A) GPCR
AMG-2674 TRPV1 Ion channel
KW 8232 Prostaglandin Receptors GPCR
MDL 28170 Calpain I / II (CAPN1, CAPN2) Cysteine protease
SB-616234-A 5-HT1B serotonin receptor (HTR1B) GPCR
SL-11128 Unknown Unspecified
Z LVG CHN2 cysteine proteinase produced by group A streptococci Cysteine protease


Want to reply?

You must be signed in to MyRSC to respond to forum posts. If you're not currently a member, you can register for free.